From 6e840971e950589bb9a54e44cb81d2856c7e7796 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 8 May 2026 17:43:32 +0000 Subject: [PATCH] vida: extract claims from 2026-03-05-omada-health-fy2025-results-first-profitable-quarter - Source: inbox/queue/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...20-percentage-points-through-coaching-and-monitoring.md | 7 +++++++ ...omada-health-fy2025-results-first-profitable-quarter.md | 5 ++++- 2 files changed, 11 insertions(+), 1 deletion(-) rename inbox/{queue => archive/health}/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md (98%) diff --git a/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md b/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md index 4f3607edb..dffe4cb02 100644 --- a/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md +++ b/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md @@ -74,3 +74,10 @@ Noom's microdose GLP-1Rx users showed 77.8% engagement with the app for 4+ weeks **Source:** Omada Health clinical outcomes data, March 2026 Omada members who persisted on GLP-1 for 12 months achieved 18.4% average weight loss and 44% greater weight loss on semaglutide versus real-world evidence, suggesting behavioral support improves not just persistence but also on-medication efficacy. + + +## Supporting Evidence + +**Source:** Omada Health FY2025 earnings report, March 5, 2026 + +Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 47-49% comparison cohort, representing 18-20 percentage point improvement. Persistent members achieved 18.4% average weight loss at 12 months; overall cohort 16.3% (44% better than semaglutide real-world evidence). This confirms behavioral support creates measurable persistence and outcome improvements. diff --git a/inbox/queue/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md b/inbox/archive/health/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md similarity index 98% rename from inbox/queue/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md rename to inbox/archive/health/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md index 80176d05c..1a4c0d982 100644 --- a/inbox/queue/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md +++ b/inbox/archive/health/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md @@ -7,10 +7,13 @@ date: 2026-03-05 domain: health secondary_domains: [] format: earnings-report -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-08 priority: high tags: [Omada, digital-health, GLP-1, behavioral-health, atoms-to-bits, VBC, employer-market, IPO] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content